| Name | Title | Contact Details |
|---|
Fieldtex Products Inc is a Rochester, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Portal Instruments is transforming the delivery of modern medicines and enhancing the standard of care for chronic diseases. Portal`s unique platform technology is capable of injecting today`s new biological drugs, regardless of volume or viscosity, with minimal sensation and time, providing the patient with enabling connectivity to optimize their disease challenges. The computer-controlled delivery technology is silent, innocuous, and highly customizable across a large variety of medical, animal, agricultural, and cosmetic applications.
MedShift, founded in 2015 in Charlotte, NC delivers platform as a service to both medical device manufacturers as well as individual medical practices. Foundationally MedShift enables access to the latest devices and technology to remain competitive and attract new business. MedShift has partnered with over 250 providers in North America, Australia, and New Zealand to give practices the latest in cutting-edge treatment modalities, services, and systems. MedShift is disrupting the traditional aesthetic device market by offering permanent placement, holistic subscription services for surgeons, physicians and their business. MedShift`s broad portfolio of services for practices includes a portfolio of 24 leading aesthetic medical devices from six manufacturers, an aesthetic eCommerce and subscription platform, in-house communications and marketing services, and inbound lead generation. For manufacturers MedShift delivers a highly secure IoT platform consisting of both hardware and software assets allowing for real time visibility, remote management, and big data modeling of entire medical device lineups. MedShift adds value across manufacturer and provider spectrum and continues to empower robust integration with leading brands and doctors in the industry.
John R. Dwyer, Jr., JD, serves as the Chief Financial Officer and General Counsel of Telcare, Inc. Mr. Dwyer served as Principal of CodeRyte, Inc. He served as an Executive Vice President of Doctors Health, Inc. and also served as its Chief Financial Officer for 2 years. He served as a Principal of Graham, Hamilton & Dwyer, Inc. (“GHD“). He served as Chief Executive Officer of e-MEDx. He served as Chief Operating Officer of Active Health Management. He served as Chief Executive Officer of Vetcentric, a specialty on-line pharmacy. Mr. Dwyer served at Diametrics, Inc., where he served as President of California-based high technology Company. Mr. Dwyer began his professional career as an Attorney with Arent, Fox, Kintner, Plotkin & Kahn, the fifth largest law firm in Washington, D.C., where he focused on transactions in the health care and telecommunications industries. He serves as the Chairman of Redbricks.com, LLC. He serves on the Boards of a number of private and not-for-profit organizations including Earth Conservation Corp. He serves as a Director of the Trust for America's Health. He serves on the Executive Council of Leaders Engaged against Alzheimer's Disease (LEAD). He serves as a Director of USAgainstAlzheimer's. He served as the Chairman of Telcare, Inc. and serves as its Director. He served as a Director of CodeRyte, Inc. Mr. Dwyer served as a Member of the Obama Administration's HHS transition team and has played an active role in the HHS, FDA, and Commerce transition and staffing plans of the Administration. He co-founded the first political action committee focused on a particular disease, the Alzheimer's Action PAC. Mr. Dwyer is a frequent Speaker on financing and regulatory issues of critical importance to emerging health technology companies. He has spoken on health information issues, business risks associated with the FDA approval process, and patent insurance at a variety of forums including the BIO/CEO and AdvaMed annual conferences. Mr. Dwyer is a graduate of Marquette University and the Cornell University Law School.
Still River Systems is dedicated to providing physicians and their patients access to high quality, cost-effective proton therapy solutions, and to helping establish this superior treatment modality as a standard of care for patients worldwide.